Search

Start Over Subject terguride

1. Effect of terguride on insulin binding, insulinaemia, glucose tolerance and hyperlipaemia in lean SHR Koletsky rats

Creator:
Golda, V. and Hilgertová, J.
Type:
article, model:article, and TEXT
Subject:
glucose tolerance, insulin binding, insulinaemia, fat pads, plasma cholesterol, plasma triglycerides, and terguride
Language:
English
Description:
Glucose tolerance, insulin binding to erythrocytes, insulinaemia, plasma total cholesterol, plasma triglycerides, weight of fat pads, food consumption and body weight changes were studied in genetically hypertensive lean Koletsky rats. Long-term treatment with dopaminergic agonist terguride (0.2 mg/kg/day) normalized glucose tolerance and increased the percentage of bound insulin to erythrocytes in both sexes. Terguride decreased insulinaemia, cholesterolaemia, fat pads and body weight only in female rats. Food consumption was not influenced by terguride over the injection period.
Rights:
http://creativecommons.org/licenses/by-nc-sa/4.0/ and policy:public

2. Independence of estrogen-induced pituitary proliferation on local IGF-I mRNA and EGF inRNA expression. modifying effects of tamoxifen and terguride

Creator:
Hána, V., Haluzík, M., and Schreiber, V.
Type:
article, model:article, and TEXT
Subject:
estrogen induced pituitary proliferation, IGF-I mRNA, EGF mRNA, tamoxifen, terguride, and RT PCR
Language:
English
Description:
Pituitary hyperplasia as well as proliferation of the endometrium are typical responses to estrogen administration in rodents. Both insulin-like growth factor-I (IGF-I) and epidermal growth factor (EGF) have been implicated as paracrine mediators and amplifiers of estrogen action in the rodent uterus. The auto/paracrine role of IGF-I, EGF, their receptors and IGF binding proteins in pituitary proliferation has not yet been solved. Here we have used a semi-quantitative reverse transcription polymerase chain reaction (RT PCR) assay to demonstrate the changes in IGF-I mRNA and EGF mRNA abundance in the proliferating male rat pituitary in response to estradiol benzoate (EB; 1 mg/kg b.w. twice weekly i.m. for 3 weeks) and modifying effect of drugs antagonizing the pituitary enlargement — antiestrogen tamoxifen (TAM, 5 mg/kg b.w. daily) and also the dopaminergic agonist terguride (TER, 0.66 mg/kg b.w. daily, routinely used for the treatment of prolactinomas). In three separate experiments, EB induced a 2.2-2.5 fold increase in pituitary weight. The abundance of IGF-I and EGF mRNAs in pituitaries of EB-treated animals did not differ from the controls in two experiments and in the third series with the most marked pituitary hyperplasia mRNAs of both growth factors were even significantly decreased. Antiestrogen TAM administered with EB partially blocked the EB-induced proliferation and significantly stimulated IGF-I mRNA (p = 0.003) and EGF mRNA (p = 0.023) expression, while EB or TAM alone did not stimulate mRNAs of the studied growth factors. Significant antiproliferative effect of dopaminergic agonist TER on EB-induced pituitary proliferation (p = 0.006) was accompanied with decreased IGF-I mRNA (p = 0.025), but not EGF mRNA abundance. Our results suggest that the estrogen-induced pituitary proliferation is independent of the local expression of IGF-I and EGF mRNAs.
Rights:
http://creativecommons.org/licenses/by-nc-sa/4.0/ and policy:public

3. Terguride but not bromocriptine alleviated glucose tolerance abnormalities and hyperlipidaemia in obese and lean genetically hypertensive Koletsky rats

Creator:
Golda, V. and Cvak, L.
Type:
article, model:article, and TEXT
Subject:
glucose tolerance abnormalities, hyperlipidaemia, Koletsky SHR/N-cp rats, terguride, and bromocriptine
Language:
English
Description:
Glucose tolerance, total plasma cholesterol and plasma triglycerides were studied in the genetically hypertensive obese Koletsky rats (SHR/N-cp) and in their lean siblings. The initial part of the glucose tolerance curve was substantially elevated in both obese and lean Koletsky animals compared to normotensive Wistar rats. The abnormal glucose tolerance in hypertensive rats was accompanied by increased total plasma cholesterol and plasma triglycerides. Long-term treatment with dopaminergic agonists terguride or bromocriptine (0.2 and 2.0 mg/kg/day, respectively) exerted similar effects on lipid metabolism but both drugs differed in their influence on glucose tolerance. Terguride lowered plasma lipids and normalized glucose tolerance in both obese and lean Koletsky rats. Bromocriptine reduced hyperlipidaemia but did not attenuate the abnormalities of glucose tolerance in either lean or obese Koletsky animals.
Rights:
http://creativecommons.org/licenses/by-nc-sa/4.0/ and policy:public